PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation

Disease relapse remains the leading cause of failure after autologous stem cell transplantation (ASCT) for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). We conducted a phase 2, multicenter, single-arm study of the anti–PD-1 monoclonal antibody pembrolizumab given after...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Adv
Главные авторы: Frigault, Matthew J., Armand, Philippe, Redd, Robert A., Jeter, Erin, Merryman, Reid W., Coleman, Kimberly C., Herrera, Alex F., Dahi, Parastoo, Nieto, Yago, LaCasce, Ann S., Fisher, David C., Ng, Samuel Y., Odejide, Oreife O., Freedman, Arnold S., Kim, Austin I., Crombie, Jennifer L., Jacobson, Caron A., Jacobsen, Eric D., Wong, Jeffrey L., Bsat, Jad, Patel, Sanjay S., Ritz, Jerome, Rodig, Scott J., Shipp, Margaret A., Chen, Yi-Bin, Joyce, Robin M.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2020
Предметы:
Lymphoid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6960482/
https://ncbi.nlm.nih.gov/pubmed/31917843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000784
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы